Raymond James Financial Services Advisors Inc. reduced its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 22.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 59,432 shares of the company’s stock after selling 16,755 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $932,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. State Board of Administration of Florida Retirement System boosted its holdings in Teva Pharmaceutical Industries by 3.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 49,181 shares of the company’s stock worth $758,000 after buying an additional 1,681 shares during the last quarter. AGF Investments America Inc. lifted its stake in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock worth $930,000 after purchasing an additional 1,458 shares in the last quarter. Bank of Montreal Can lifted its stake in Teva Pharmaceutical Industries by 7.3% in the 1st quarter. Bank of Montreal Can now owns 570,059 shares of the company’s stock worth $8,938,000 after purchasing an additional 38,659 shares in the last quarter. Lindbrook Capital LLC lifted its stake in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after purchasing an additional 945 shares in the last quarter. Finally, Norges Bank purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $146,130,000. 65.08% of the stock is currently owned by institutional investors.
In related news, VP Notaristefani Carlo De sold 16,070 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the sale, the vice president now directly owns 49,659 shares of the company’s stock, valued at $567,105.78. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Sol J. Barer purchased 111,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, June 3rd. The stock was bought at an average cost of $8.98 per share, with a total value of $996,780.00. Following the completion of the transaction, the director now owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is owned by insiders.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same quarter in the previous year, the firm posted $0.94 earnings per share. The company’s revenue was down 15.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.27 earnings per share for the current year.
TEVA has been the topic of several analyst reports. UBS Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, March 7th. They set a “buy” rating and a $22.00 price target on the stock. CIBC upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Monday, June 3rd. SunTrust Banks began coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, March 19th. They issued a “hold” rating and a $17.00 target price for the company. Wells Fargo & Co dropped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $18.00 and set a “market perform” rating for the company in a report on Wednesday, April 3rd. Finally, BMO Capital Markets initiated coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, March 28th. They issued a “market perform” rating and a $18.00 target price for the company. Five investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $16.00.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: The Discount Rate – What You Need to Know
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.